#Cardiovascular outcomes
MACE, HFpEF, CV death, the trials that move guidelines.
Diabetes Drugs and Cardiovascular Outcomes
A 93-trial network meta-analysis linked several diabetes drug classes with fewer cardiovascular events, while indirect comparisons limit treatment rankings.
SURPASS-CVOT Beyond MACE
A 2026 commentary argues that SURPASS-CVOT may require endpoints beyond MACE, but its biological framework remains a hypothesis, not new trial evidence.
Tirzepatide in Heart Failure: Review
A 2026 meta-analysis links tirzepatide to lower cardiorenal biomarkers, while functional and kidney findings remain based on single trials.
Oral semaglutide and arterial stiffness
A retrospective cohort linked higher-dose oral semaglutide and SGLT-2 inhibitor use with improved arterial stiffness, without proving causation.
REDEFINE 3: CagriSema Trial Design
REDEFINE 3 has published its CagriSema trial design and baseline cohort, but cardiovascular outcome results remain pending.
GLP-1 Drugs and OSA Complication Risk
A five-year database study linked GLP-1 drugs to fewer lung complications in people with sleep apnea and type 2 diabetes, without proving causation.
How Tirzepatide May Raise Heart Rate
A human stem-cell study links tirzepatide to faster pacemaker-cell beating through cAMP and calcium signalling, but it is not a patient trial.
GLP-1 Heart Failure Meta-analysis
A 14-trial meta-analysis found a favorable signal in HFpEF, while evidence for GLP-1 receptor agonists in HFrEF remained limited.
GLP-1 Drugs and Kidney Outcomes in CKD
Thirteen GLP-1 receptor agonist trials pooled in chronic kidney disease show fewer heart and kidney events, with semaglutide topping an exploratory ranking.
Semaglutide and Heart-Failure Hemodynamics
A new case report describes semaglutide easing heart-failure pressures in one patient, but a single case can't prove a population-wide effect.
Oral Semaglutide and Cognitive Decline Risk
A small elderly-cohort study links oral semaglutide to less cognitive impairment than DPP-4 inhibitors, but a large Alzheimer's trial found no benefit.
Semaglutide vs SGLT2is in Kidney Disease
A new network meta-analysis compares semaglutide, SGLT2 inhibitors and finerenone on heart and kidney outcomes in diabetic kidney disease.